Defendant
1 case as defendant.
Jina Pharmaceuticals Inc. is a private biotechnology company headquartered in Libertyville, Illinois, United States, and was founded in 1969. The company has approximately 38 employees and an reported annual revenue of $53.5 million.
Jina Pharmaceuticals Inc. is engaged in the research, development, and commercialization of therapeutic products for treating cancer, infectious diseases, and acute medical emergencies. The company leverages its proprietary Nanoaqualip technology in its drug formulation efforts. Its pipeline includes small molecule drugs and candidates such as Endoxifen, JIN-2016, and JIN-2017, targeting conditions like neoplasms and nervous system diseases. Jina Pharmaceuticals Inc. is also involved in clinical trials, including for Endoxifen in Bipolar I Disorder.
In terms of patent litigation, Jina Pharmaceuticals Inc. appears to be an operating company that defends its intellectual property. The company has one tracked case, where it is listed as a defendant and has not appeared as a plaintiff. This single case, Atossa Therapeutics Inc. v. Jina Pharmaceuticals Inc., is being litigated at the Patent Trial and Appeal Board (PTAB) and commenced on 2025-12-10.
A Post-Grant Review (PGR) proceeding before the Patent Trial and Appeal Board (PTAB) initiated by Atossa Therapeutics Inc. against Jina Pharmaceuticals Inc., which concluded in a settlement.